BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Martín-varillas JL, Calvo-río V, Beltrán E, Sánchez-bursón J, Mesquida M, Adán A, Hernandez MV, Garfella MH, Pascual EV, Martínez-costa L, Sellas-fernández A, Cordero-coma M, Díaz-llopis M, Gallego R, Salom D, Ortego N, García-serrano JL, Callejas-rubio J, Herreras JM, García-aparicio Á, Maíz O, Blanco A, Torre I, Díaz-valle D, Pato E, Aurrecoechea E, Caracuel MA, Gamero F, Minguez E, Carrasco-cubero C, Olive A, Vázquez J, Ruiz-moreno O, Manero J, Muñoz-fernández S, Martinez MG, Rubio-romero E, Toyos-sáenz de Miera FJ, López Longo FJ, Nolla JM, Revenga M, González-vela C, Loricera J, Atienza-mateo B, Demetrio-pablo R, Hernández JL, González-gay MA, Blanco R. Successful Optimization of Adalimumab Therapy in Refractory Uveitis Due to Behçet's Disease. Ophthalmology 2018;125:1444-51. [DOI: 10.1016/j.ophtha.2018.02.020] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 7.5] [Reference Citation Analysis]
Number Citing Articles
1 Patel S, Belamkar A, Hajrasouliha AR, Jusufbegovic D, Ciulla TA. Progress in the pharmacotherapy of uveitis: the art of personalized care. Expert Opin Pharmacother 2022. [PMID: 35880543 DOI: 10.1080/14656566.2022.2104637] [Reference Citation Analysis]
2 van der Houwen TB, van Hagen PM, van Laar JAM. Immunopathogenesis of Behçet's disease and treatment modalities. Semin Arthritis Rheum 2022;52:151956. [PMID: 35038644 DOI: 10.1016/j.semarthrit.2022.151956] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 Uzlu D, Köse B, Akyol N, Erdöl H, Günay M. The evaluation of the efficacy of adalimumab in refractory non-infectious uveitis with ultra-widefield fundus fluorescein angiography. Int Ophthalmol 2022. [PMID: 34985713 DOI: 10.1007/s10792-021-02209-x] [Reference Citation Analysis]
4 Salido Olivares M, Loza Santamaría E. Efficacy and safety of the optimisation of biological therapy in non-infectious uveitis: Systematic review. Semin Arthritis Rheum 2022;:151944. [PMID: 35027247 DOI: 10.1016/j.semarthrit.2021.11.010] [Reference Citation Analysis]
5 Hatemi G. A treat-to-target approach is needed for Behçet's syndrome. Curr Opin Rheumatol 2022;34:39-45. [PMID: 34710886 DOI: 10.1097/BOR.0000000000000854] [Reference Citation Analysis]
6 Zhang M, Liu J, Liu T, Han W, Bai X, Ruan G, Lv H, Shu H, Li Y, Li J, Tan B, Zheng W, Xu H, Zheng W, Yang H, Qian J. The efficacy and safety of anti-tumor necrosis factor agents in the treatment of intestinal Behcet's disease, a systematic review and meta-analysis. J Gastroenterol Hepatol 2021. [PMID: 34894004 DOI: 10.1111/jgh.15754] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Standardization of Uveitis Nomenclature (SUN) Working Group. Classification Criteria for Behçet Disease Uveitis. Am J Ophthalmol 2021;228:80-8. [PMID: 33845008 DOI: 10.1016/j.ajo.2021.03.058] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 13.0] [Reference Citation Analysis]
8 Citirik M, Ucgul Atilgan C, Rahmanlar H, Alkan A, Gursoz H. Biological therapy for ocular Behçet's disease with off-label drug prescription in Turkey. Eur J Hosp Pharm 2021:ejhpharm-2021-002785. [PMID: 34083220 DOI: 10.1136/ejhpharm-2021-002785] [Reference Citation Analysis]
9 Gueudry J, Leclercq M, Saadoun D, Bodaghi B. Old and New Challenges in Uveitis Associated with Behçet's Disease. J Clin Med 2021;10:2318. [PMID: 34073249 DOI: 10.3390/jcm10112318] [Reference Citation Analysis]
10 Soheilian M, Ebrahimiadib N, Hedayatfar A, Hosseini M, Zarei M, Anjidani N. Efficacy of Biosimilar Adalimumab in the Treatment of Behçet's Uveitis. Ocul Immunol Inflamm 2021;:1-6. [PMID: 33826486 DOI: 10.1080/09273948.2021.1900276] [Reference Citation Analysis]
11 Hiyama T, Harada Y, Kiuchi Y. Efficacy and Safety of Adalimumab Therapy for the Treatment of Non-infectious Uveitis: Efficacy comparison among Uveitis Aetiologies. Ocul Immunol Inflamm 2021;:1-8. [PMID: 33560160 DOI: 10.1080/09273948.2020.1857791] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 El Jammal T, Loria O, Jamilloux Y, Gerfaud-Valentin M, Kodjikian L, Sève P. Uveitis as an Open Window to Systemic Inflammatory Diseases. J Clin Med 2021;10:E281. [PMID: 33466638 DOI: 10.3390/jcm10020281] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Tugal-Tutkun I, Çakar Özdal P. Behçet's disease uveitis: is there a need for new emerging drugs? Expert Opin Emerg Drugs 2020;25:531-47. [PMID: 33147420 DOI: 10.1080/14728214.2020.1847271] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
14 Leclercq M, Desbois AC, Domont F, Maalouf G, Touhami S, Cacoub P, Bodaghi B, Saadoun D. Biotherapies in Uveitis. J Clin Med 2020;9:E3599. [PMID: 33171664 DOI: 10.3390/jcm9113599] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Martín-Varillas JL, Atienza-Mateo B, Calvo-Rio V, Beltrán E, Sánchez-Bursón J, Adán A, Hernández-Garfella M, Valls-Pascual E, Sellas-Fernández A, Ortego N, Maíz O, Torre I, Fernández-Espartero C, Jovani V, Peiteado D, Valle DD, Aurrecoechea E, Caracuel MA, García-González AJ, Álvarez ER, Vegas-Revenga N, Demetrio-Pablo R, Castañeda S, González-Gay MA, Hernández JL, Blanco R; Ricardo Blanco on behalf of the Spanish Collaborative Group of Refractory Behçet’s Disease. Long-term Follow-up and Optimization of Infliximab in Refractory Uveitis Due to Behçet Disease: National Study of 103 White Patients. J Rheumatol 2021;48:741-50. [PMID: 33004539 DOI: 10.3899/jrheum.200300] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
16 Sánchez-Bilbao L, Martínez-López D, Revenga M, López-Vázquez Á, Valls-Pascual E, Atienza-Mateo B, Valls-Espinosa B, Maiz-Alonso O, Blanco A, Torre-Salaberri I, Rodríguez-Méndez V, García-Aparicio Á, Veroz-González R, Jovaní V, Peiteado D, Sánchez-Orgaz M, Tomero E, Toyos-Sáenz de Miera FJ, Pinillos V, Aurrecoechea E, Mora Á, Conesa A, Fernández-Prada M, Troyano JA, Calvo-Río V, Demetrio-Pablo R, González-Mazón Í, Hernández JL, Castañeda S, González-Gay MÁ, Blanco R. Anti-IL-6 Receptor Tocilizumab in Refractory Graves' Orbitopathy: National Multicenter Observational Study of 48 Patients. J Clin Med 2020;9:E2816. [PMID: 32878150 DOI: 10.3390/jcm9092816] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Herrero-Morant A, Álvarez-Reguera C, Martín-Varillas JL, Calvo-Río V, Casado A, Prieto-Peña D, Atienza-Mateo B, Maiz-Alonso O, Blanco A, Vicente E, Rúa-Figueroa Í, Cáceres-Martin L, García-Serrano JL, Callejas-Rubio JL, Ortego-Centeno N, Narváez J, Romero-Yuste S, Sánchez J, Estrada P, Demetrio-Pablo R, Martínez-López D, Castañeda S, Hernández JL, González-Gay MÁ, Blanco R. Biologic Therapy in Refractory Non-Multiple Sclerosis Optic Neuritis Isolated or Associated to Immune-Mediated Inflammatory Diseases. A Multicenter Study. J Clin Med 2020;9:E2608. [PMID: 32796717 DOI: 10.3390/jcm9082608] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 Dominguez-casas LC, Sánchez-bilbao L, Calvo-río V, Maíz O, Blanco A, Beltrán E, Martínez-costa L, Demetrío-pablo R, del Buergo MÁ, Rubio-romero E, Díaz-valle D, Lopez-gonzalez R, García-aparicio ÁM, Mas AJ, Vegas-revenga N, Castañeda S, Hernández JL, González-gay MA, Blanco R. Biologic therapy in severe and refractory peripheral ulcerative keratitis (PUK). Multicenter study of 34 patients. Seminars in Arthritis and Rheumatism 2020;50:608-15. [DOI: 10.1016/j.semarthrit.2020.03.023] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
19 Gaggiano C, Sota J, Gentileschi S, Caggiano V, Grosso S, Tosi GM, Frediani B, Cantarini L, Fabiani C. The current status of biological treatment for uveitis. Expert Rev Clin Immunol 2020;16:787-811. [PMID: 32700605 DOI: 10.1080/1744666X.2020.1798230] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Moll-Udina A, Miguel Escuder L, Hernanz I, Llorenç V, Fonollosa A, Cordero Coma M, Sainz de la Maza M, Espinosa G, González Guijarro JJ, Lopez Lopez F, Alba-Linero C, Hernández M, Martínez Costa L, Celdrán Vivancos D, Giralt L, Artaraz J, Soler Bartrina P, Jódar Márquez M, García de Vicuña R, Esquinas C, Adán A. Adalimumab in Elderly Patients with Non-Infectious Uveitis. Safety and Efficacy. Ocul Immunol Inflamm 2020;:1-8. [PMID: 32657649 DOI: 10.1080/09273948.2020.1769139] [Reference Citation Analysis]
21 Hu Y, Huang Z, Yang S, Chen X, Su W, Liang D. Effectiveness and Safety of Anti-Tumor Necrosis Factor-Alpha Agents Treatment in Behcets' Disease-Associated Uveitis: A Systematic Review and Meta-Analysis. Front Pharmacol 2020;11:941. [PMID: 32670062 DOI: 10.3389/fphar.2020.00941] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
22 Llorenç V, Cordero-coma M, Blanco-esteban A, Heras-mulero H, Losada-castillo M, Jovani-casano V, Valls-pascual E, Jodar-marquez M, García-aparicio Á, Fonollosa A, González-guijarro JJ, Rodriguez-melian L, Fernández-prada M, Jerez-fidalgo M, Hernandez-garfella M, Esquinas C, Sainz-de-la-maza M, Adán A. Drug Retention Rate and Causes of Discontinuation of Adalimumab in Uveitis. Ophthalmology 2020;127:814-25. [DOI: 10.1016/j.ophtha.2019.11.024] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
23 van der Houwen T, van Laar J. Behҫet's Disease, and the Role of TNF-α and TNF-α Blockers. Int J Mol Sci 2020;21:E3072. [PMID: 32349254 DOI: 10.3390/ijms21093072] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Cetin Gedik K, Romano M, Berard RA, Demirkaya E. An Overview of Conventional and Recent Treatment Options for Behcet’s Disease. Curr Treat Options in Rheum 2020;6:99-127. [DOI: 10.1007/s40674-020-00143-0] [Reference Citation Analysis]
25 Yazici Y. Management of Behçet syndrome. Current Opinion in Rheumatology 2020;32:35-40. [DOI: 10.1097/bor.0000000000000666] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
26 Hiyama T, Harada Y, Doi T, Kiuchi Y. Early administration of adalimumab for paediatric uveitis due to Behçet's disease. Pediatr Rheumatol Online J 2019;17:29. [PMID: 31182107 DOI: 10.1186/s12969-019-0333-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
27 Poddighe D, Mukusheva Z, Dauyey K, Assylbekova M. Adalimumab in the treatment of pediatric Behçet’s disease: case-based review. Rheumatol Int 2019;39:1107-12. [DOI: 10.1007/s00296-019-04300-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
28 Esatoglu SN, Hatemi G. Update on the treatment of Behçet's syndrome. Intern Emerg Med 2019;14:661-75. [PMID: 30684097 DOI: 10.1007/s11739-019-02035-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
29 Rosenbaum JT. Uveitis: contrasting the approaches in Japan and the United States. Jpn J Ophthalmol 2019;63:1-6. [DOI: 10.1007/s10384-018-0633-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]